Every 10-Q that Sanara MedTech Inc. (SMTI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SMTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SMTI filings page.
Sanara MedTech Inc. reported higher sales for the quarter and six months ended June 30, 2026, while essentially breaking even year-to-date after winding down its THP segment. Net revenue rose to $28.1 million in the quarter and $55.9 million for six months, driven mainly by soft tissue repair products. Operating income from continuing operations was $1.8 million for the quarter and $4.4 million year-to-date, but higher interest and equity-method losses produced a quarterly net loss attributable to shareholders of $452,864. For the six months, net income attributable to shareholders was $6,093, compared with a significant loss a year earlier, as discontinued THP operations no longer weigh on results.
Cash from operating activities was $(426,935) for the six months, reflecting lower accrued bonuses and higher interest payments. Cash and cash equivalents were $15.4 million and long-term debt under the CRG Term Loan was $46.5 million, with annual minimum revenue covenants rising to $85.0 million for 2026. Shareholders’ equity increased to $7.9 million, supported by share-based compensation and reduced accumulated deficit.
Sanara MedTech Inc. reported stronger results for the quarter ended March 31, 2026. Net revenue rose to $27,798,534 from $23,434,096 a year earlier, driven mainly by growth in soft tissue repair products. Gross profit increased to $25,874,945, while operating income improved to $2,646,581.
The company generated net income of $458,603, or $0.05 per diluted share, compared with a net loss of $3,527,383 in the prior-year quarter, helped by small income from discontinued THP operations. Cash declined to $13,594,459 as net cash used in operating activities was $2,465,407. Long-term debt under the CRG term loan was $46,226,422.
Sanara MedTech Inc. (SMTI) reported stronger continuing operations for the quarter ended September 30, 2025. Net revenue rose to $26,333,819 from $21,671,599 a year ago, led by soft tissue repair products ($23,424,126) and bone fusion products ($2,909,693). Gross profit increased to $24,459,605, and operating income from continuing operations improved to $2,941,240 versus $778,537 last year. Continuing operations posted net income of $834,493 in Q3 and $714,186 year‑to‑date.
The company discontinued its THP segment in mid‑September and recorded an asset impairment charge of $26,472,407, driving Q3 net loss to $(30,412,108) and year‑to‑date net loss to $(35,957,889). Cash was $14,939,646 with positive operating cash flow of $2,841,568 for the nine months. Long‑term debt increased to $45,089,787, contributing to higher interest expense ($1,818,105 in Q3). Shareholders’ equity declined to $6,140,534. As of November 11, 2025, 8,935,657 common shares were outstanding.
Sanara MedTech Inc. reported quarterly net revenue of $25.83 million and six‑month net revenue of $49.26 million, increases versus the prior year driven by higher sales of soft tissue repair and bone fusion products. Gross profit rose to $23.89 million for the quarter, reflecting strong product margins despite modest cost of goods sold.
The company recorded a net loss attributable to shareholders of $2.01 million for the quarter (net loss per share $0.23), improved from a loss of $3.50 million the prior year quarter; year‑to‑date net loss was $5.54 million (vs. $5.27 million prior year). Cash increased to $16.96 million and total assets grew to $98.77 million. Leverage rose materially: long‑term debt, net of issuance costs, was $44.22 million (up from $30.69 million) following additional borrowings under the CRG Term Loan. The company completed the CarePICS acquisition on April 1, 2025 (total purchase consideration $3.48 million) and recorded higher investments and earnout liabilities. The period shows revenue growth and improved quarterly profitability but higher interest and contingent obligations from financing and acquisitions.